专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07754200B2 Phosphate transport inhibitors 有权
标题翻译：磷酸盐转运抑制剂
公开(公告)号：US07754200B2
公开(公告)日：2010-07-13
申请号：US11438679
申请日：2006-05-22
申请人： Thomas H. Jozefiak , Cecilia M. Bastos , Chad C. Huval
发明人： Thomas H. Jozefiak , Cecilia M. Bastos , Chad C. Huval
IPC分类号： A61K31/74
CPC分类号： C07F9/65502 , C07F9/3821 , C07F9/4012 , C07F9/5537 , C08F8/40 , C08F30/02 , Y02P20/55
摘要： Disclosed is a phosphate transport inhibiting compound represented by Structural Formula (I): R1 and R2 are independently —H, an electron withdrawing group or a C1-C10 alkyl group. Y is a covalent bond, a substituted methylene group, an unsubstituted methylene group or —CR1R2P(O)(OH)—. R3 is a hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups, a substituted hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups, a heteroaryl group, a substituted heteroaryl group or a phenyl group substituted with one or more groups selected from —Cl, —Br, —F, —CN, —NO2, —ORa, —N(Ra)2, —COORa, —CON(Ra)2, —CORa, —S(O)Ra, —S(O)2Ra, —S(O)2N(Ra)2, —NRaS(O)2Ra, —NRaCORa, a halogenated lower alkyl group, an aryl group, a substituted aryl group, or a halogenated alkoxy group. Each Ra is independently —H, lower alkyl, substituted lower alkyl, aryl or substituted aryl.Each Rb is independently —H, a lower alkyl group, or a phosphate protecting group.
摘要翻译：公开了由结构式（I）表示的磷酸盐转运抑制化合物：R1和R2独立地为-H，吸电子基团或C1-C10烷基。 Y是共价键，取代亚甲基，未取代的亚甲基或-CR 1 R 2 P（O）（OH） - 。 R3是任选地包含一个或多个胺，铵，醚，硫醚或亚苯基连接基团的烃基，任选地包含一个或多个胺，铵，醚，硫醚或亚苯基连接基团的取代的烃基，杂芳基，取代的杂芳基被一个或多个选自-Cl，-Br，-F，-CN，-NO 2，-OR a，-N（R a）2，-COOR a，-CON（R a）2，-COR a ，-S（O）R a，-S（O）2 R a，-S（O）2 N（R a）2，-NR a（O）2 R a，-NR a COR a，卤代低级烷基，芳基，取代的芳基，或卤代烷氧基。每个R a独立地为-H，低级烷基，取代的低级烷基，芳基或取代的芳基。每个R b独立地是-H，低级烷基或磷酸酯保护基。

2. 发明授权

US07109184B2 Phosphate transport inhibitors 有权
公开(公告)号：US07109184B2
公开(公告)日：2006-09-19
申请号：US10392280
申请日：2003-03-19
申请人： Thomas H. Jozefiak , Cecilia M. Bastos , Chad C. Huval
发明人： Thomas H. Jozefiak , Cecilia M. Bastos , Chad C. Huval
IPC分类号： A10N57/00 , A61K31/675
CPC分类号： C07F9/65502 , C07F9/3821 , C07F9/4012 , C07F9/5537 , C08F8/40 , C08F30/02 , Y02P20/55
摘要： Disclosed is a phosphate transport inhibiting compound represented by Structural Formula (I): R1 and R2 are independently —H, an electron withdrawing group or a C1–C10 alkyl group. Y is a covalent bond, a substituted methylene group, an unsubstituted methylene group or —CR1R2P(O)(OH)—. R3 is a hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups, a substituted hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups, a heteroaryl group, a substituted heteroaryl group or a phenyl group substituted with one or more groups selected from —Cl, —Br, —F, —CN, —NO2, —ORa, —N(Ra)2, —COORa, —CON(Ra)2, —CORa, —S(O)Ra, —S(O)2Ra, —S(O)2N(Ra)2, —NRaS(O)2Ra, —NRaCORa, a halogenated lower alkyl group, an aryl group, a substituted aryl group, or a halogenated alkoxy group. Each Ra is independently —H, lower alkyl, substituted lower alkyl, aryl or substituted aryl. Each Rb is independently —H, a lower alkyl group, or a phosphate protecting group.

3. 发明申请

US20120322787A1 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS 有权
标题翻译： 2-乙酰氨基酚类型葡萄糖苷合成酶抑制剂
公开(公告)号：US20120322787A1
公开(公告)日：2012-12-20
申请号：US13595349
申请日：2012-08-27
申请人： Craig Siegel , Cecilia M. Bastos , David J. Harris , Angeles Dios , Edward Lee , Richard Silva , Lisa M. Cuff , Mikaela Levine , Cassandra A. Celatka , Frederic Vinick , Thomas H. Jozefiak , Yibin Xiang , John Kane , Junkai Liao
发明人： Craig Siegel , Cecilia M. Bastos , David J. Harris , Angeles Dios , Edward Lee , Richard Silva , Lisa M. Cuff , Mikaela Levine , Cassandra A. Celatka , Frederic Vinick , Thomas H. Jozefiak , Yibin Xiang , John Kane , Junkai Liao
IPC分类号： A61K31/4025 , A61P3/10 , A61P13/12 , C07D409/14 , A61K31/4439 , A61K31/397 , A61K31/422 , C07D417/14 , A61K31/428 , A61K31/4245 , A61K31/444 , A61K31/5377 , C07D405/10 , C07D413/14
CPC分类号： C07D417/14 , C07D295/125 , C07D319/18 , C07D405/06 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D409/14 , C07D411/12 , C07D413/12 , C07D413/14
摘要： A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
摘要翻译：化合物由结构式（I）表示：或其药学上可接受的盐。药物组合物包含由结构式（I）表示的化合物或其药学上可接受的盐。治疗有需要的受试者的方法包括向受试者施用治疗有效量的由结构式（I）表示的化合物或其药学上可接受的盐。受试者患有2型糖尿病; 肾脏肥大或与糖尿病肾病相关的增生; 泰撒戈谢的或法布里氏病。分别在有需要的受试者中降低血浆TNF-α，降低血糖水平，降低糖化血红蛋白水平，抑制葡萄糖神经酰胺合成酶和降低糖鞘醇浓度的方法包括向受试者施用治疗有效量的由结构式（ I）或其药学上可接受的盐。

4. 发明授权

US09272996B2 2-acylaminopropoanol-type glucosylceramide synthase inhibitors 有权
标题翻译： 2-酰基氨基丙醇型葡萄糖神经酰胺合成酶抑制剂
公开(公告)号：US09272996B2
公开(公告)日：2016-03-01
申请号：US13595251
申请日：2012-08-27
申请人： Craig Siegel , Cecilia M. Bastos , David J. Harris , Angeles Dios , Edward Lee , Richard Silva , Lisa M. Cuff , Mikaela Levine , Cassandra A. Celatka , Thomas H. Jozefiak , Frederic Vinick , Yibin Xiang , John Kane , Junkai Liao
发明人： Craig Siegel , Cecilia M. Bastos , David J. Harris , Angeles Dios , Edward Lee , Richard Silva , Lisa M. Cuff , Mikaela Levine , Cassandra A. Celatka , Thomas H. Jozefiak , Frederic Vinick , Yibin Xiang , John Kane , Junkai Liao
IPC分类号： A61K31/397 , A61K31/5377 , A61K31/44 , A61K31/325 , A61K31/42 , A61K31/40 , C07D207/12 , C07D271/12 , C07D317/60 , C07D319/18 , C07D333/16 , C07D407/12 , C07D409/04 , C07D413/04 , C07D417/12 , C07C271/12 , C07D319/20 , C07D407/06
CPC分类号： A61K31/4025 , C07C271/12 , C07D207/12 , C07D317/60 , C07D319/18 , C07D319/20 , C07D333/16 , C07D407/06 , C07D407/12 , C07D409/04 , C07D413/04 , C07D417/12
摘要： A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
摘要翻译：用于治疗多囊肾病的化合物由结构式（I）表示：或其药学上可接受的盐。药物组合物包含由结构式（I）表示的化合物或其药学上可接受的盐。在有需要的受试者中治疗多囊肾病的方法包括向受试者施用治疗有效量的由结构式（I）表示的化合物或其药学上可接受的盐。分别在有需要的受试者中治疗多囊肾病的方法包括向受试者施用治疗有效量的由结构式（I）表示的化合物或其药学上可接受的盐。

5. 发明授权

US08304447B2 2-acylaminopropoanol-type glucosylceramide synthase inhibitors 有权
标题翻译： 2-酰基氨基丙醇型葡萄糖神经酰胺合成酶抑制剂
公开(公告)号：US08304447B2
公开(公告)日：2012-11-06
申请号：US12601871
申请日：2008-05-30
申请人： Craig Siegel , Cecilia M. Bastos , David J. Harris , Angeles Dios , Edward Lee , Richard Silva , Lisa M. Cuff , Mikaela Levine , Cassandra A. Celatka , Frederic Vinick , Thomas H. Jozefiak , Yibin Xiang , John Kane , Junkai Liao
发明人： Craig Siegel , Cecilia M. Bastos , David J. Harris , Angeles Dios , Edward Lee , Richard Silva , Lisa M. Cuff , Mikaela Levine , Cassandra A. Celatka , Frederic Vinick , Thomas H. Jozefiak , Yibin Xiang , John Kane , Junkai Liao
IPC分类号： A61K31/40 , A61K31/4025 , C07D207/04 , C07D405/02
CPC分类号： C07D417/14 , C07D295/125 , C07D319/18 , C07D405/06 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D409/14 , C07D411/12 , C07D413/12 , C07D413/14
摘要： A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
摘要翻译：化合物由结构式（I）表示：或其药学上可接受的盐。药物组合物包含由结构式（I）表示的化合物或其药学上可接受的盐。治疗有需要的受试者的方法包括向受试者施用治疗有效量的由结构式（I）表示的化合物或其药学上可接受的盐。受试者患有2型糖尿病; 肾脏肥大或与糖尿病肾病相关的增生; 泰撒戈谢的或法布里氏病。分别在有需要的受试者中降低血浆TNF-α，降低血糖水平，降低糖化血红蛋白水平，抑制葡萄糖神经酰胺合成酶和降低糖鞘醇浓度的方法包括向受试者施用治疗有效量的由结构式（ I）或其药学上可接受的盐。

6. 发明授权

US08940776B2 2-acylaminopropoanol-type glucosylceramide synthase inhibitors 有权
标题翻译： 2-酰基氨基丙醇型葡萄糖神经酰胺合成酶抑制剂
公开(公告)号：US08940776B2
公开(公告)日：2015-01-27
申请号：US13595349
申请日：2012-08-27
申请人： Craig Siegel , Cecilia M. Bastos , David J. Harris , Angeles Dios , Edward Lee , Richard Silva , Lisa M. Cuff , Mikaela Levine , Cassandra A. Celatka , Frederic Vinick , Thomas H. Jozefiak , Yibin Xiang , John Kane , Junkai Liao
发明人： Craig Siegel , Cecilia M. Bastos , David J. Harris , Angeles Dios , Edward Lee , Richard Silva , Lisa M. Cuff , Mikaela Levine , Cassandra A. Celatka , Frederic Vinick , Thomas H. Jozefiak , Yibin Xiang , John Kane , Junkai Liao
IPC分类号： A61K31/42 , A61K31/4245 , A61K31/427 , A61K31/428 , A61K31/4025 , A61K31/40 , C07D277/20 , C07D277/62 , C07D261/06 , C07D405/02 , C07D271/06 , C07D207/04 , C07D295/125 , C07D319/18 , C07D405/06 , C07D405/12 , C07D407/12 , C07D409/12 , C07D409/14 , C07D411/12 , C07D413/12 , C07D413/14
CPC分类号： C07D417/14 , C07D295/125 , C07D319/18 , C07D405/06 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D409/14 , C07D411/12 , C07D413/12 , C07D413/14
摘要： A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
摘要翻译：化合物由结构式（I）表示：或其药学上可接受的盐。药物组合物包含由结构式（I）表示的化合物或其药学上可接受的盐。治疗有需要的受试者的方法包括向受试者施用治疗有效量的由结构式（I）表示的化合物或其药学上可接受的盐。受试者患有2型糖尿病; 肾脏肥大或与糖尿病肾病相关的增生; 泰撒戈谢的或法布里氏病。分别在有需要的受试者中降低血浆TNF-α，降低血糖水平，降低糖化血红蛋白水平，抑制葡萄糖神经酰胺合成酶和降低糖鞘醇浓度的方法包括向受试者施用治疗有效量的由结构式（ I）或其药学上可接受的盐。

7. 发明申请

US20100256216A1 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS 有权
标题翻译： 2-乙酰氨基酚类型葡萄糖苷合成酶抑制剂
公开(公告)号：US20100256216A1
公开(公告)日：2010-10-07
申请号：US12601871
申请日：2008-05-30
申请人： Craig Siegel , Cecilia M. Bastos , David J. Harris , Angeles Dios , Edward Lee , Richard Silva , Lisa M. Cuff , Mikaela Levine , Cassandra A. Celatka , Frederic Vinick , Thomas H. Jozefiak , Yibin Xiang , John Kane , Junkai Liao
发明人： Craig Siegel , Cecilia M. Bastos , David J. Harris , Angeles Dios , Edward Lee , Richard Silva , Lisa M. Cuff , Mikaela Levine , Cassandra A. Celatka , Frederic Vinick , Thomas H. Jozefiak , Yibin Xiang , John Kane , Junkai Liao
IPC分类号： A61K31/4025 , C07D405/06 , C07D207/00 , A61K31/4015
CPC分类号： C07D417/14 , C07D295/125 , C07D319/18 , C07D405/06 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D409/14 , C07D411/12 , C07D413/12 , C07D413/14
摘要： A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
摘要翻译：化合物由结构式（I）表示：或其可药用盐。药物组合物包含由结构式（I）表示的化合物或其药学上可接受的盐。治疗有需要的受试者的方法包括向受试者施用治疗有效量的由结构式（I）表示的化合物或其药学上可接受的盐。受试者患有2型糖尿病; 肾脏肥大或与糖尿病肾病相关的增生; 泰撒戈谢的或法布里氏病。分别在有需要的受试者中降低血浆TNF-α，降低血糖水平，降低糖化血红蛋白水平，抑制葡萄糖神经酰胺合成酶和降低糖鞘醇浓度的方法包括向受试者施用治疗有效量的由结构式（ I）或其药学上可接受的盐。

8. 发明授权

US07119120B2 Phosphate transport inhibitors 有权
标题翻译：磷酸盐转运抑制剂
公开(公告)号：US07119120B2
公开(公告)日：2006-10-10
申请号：US10327627
申请日：2002-12-20
申请人： Thomas H. Jozefiak , Cecilia M. Bastos , Andrew T. Papoulis , Stephen Randall Holmes-Farley
发明人： Thomas H. Jozefiak , Cecilia M. Bastos , Andrew T. Papoulis , Stephen Randall Holmes-Farley
IPC分类号： A61K31/18 , A61K31/16 , A61K37/18
CPC分类号： A61K45/06 , A61K31/166 , A61K31/17 , A61K31/18 , A61K31/415 , A61K31/63 , A61K33/38 , A61K2300/00
摘要： Disclosed are compounds which have been identified as inhibitors of phosphate transport. Many of the compounds are represented by Structural Formula (I): Ar1—W—X—Y—Ar2; or a pharmaceutically acceptable salt thereof. Ar1 and Ar2 are independently a substituted or unsubstituted aryl group or an optionally substituted five membered or six membered non-aromatic heterocylic group fused to an optionally substituted monocylic aryl group. W and Y are independently a covalent bond or a C1–C3 substituted or unsubstituted alkylene group. X is a heteroatom-containing functional group, an aromatic heterocyclic group, substituted aromatic heterocyclic group, non-aromatic heterocyclic group, substituted non-aromatic heterocyclic group, an olefin group or a substituted olefin group. Also disclosed are methods of treating a subject with a disease associated with hyperphosphatemia, as well as a disease mediated by phosphate-transport function. The methods comprise the step of administering an effective amount of the one of the compounds described above.
摘要翻译：公开了已被鉴定为磷酸盐转运抑制剂的化合物。许多化合物由结构式（I）表示：<？in-line-formula description =“In-line Formulas”end =“lead”？> Ar -WXY-Ar _{2 <？in-line-formula description =“In-line Formulas”end =“tail”？>或其药学上可接受的盐。 Ar 1和Ar 2独立地是与任选取代的单环芳基稠合的取代或未取代的芳基或任选取代的五元或六元非芳族杂环基。 W和Y独立地是共价键或C1-C3取代或未取代的亚烷基。 X为含杂原子的官能团，芳香族杂环基，取代芳香族杂环基，非芳香族杂环基，取代非芳香族杂环基，烯基或取代烯基。还公开了治疗患有与高磷酸盐血症相关的疾病的受试者以及由磷酸盐转运功能介导的疾病的方法。所述方法包括施用有效量的上述一种化合物的步骤。}

9. 发明授权

US5476757A Photographic element containing a novel cyan dye forming coupler and process for its use 失效
标题翻译：含有新型青色染料成色剂的摄影元件及其使用方法
公开(公告)号：US5476757A
公开(公告)日：1995-12-19
申请号：US359134
申请日：1994-12-19
申请人： Philip T. S. Lau , Thomas H. Jozefiak , Thomas R. Welter
发明人： Philip T. S. Lau , Thomas H. Jozefiak , Thomas R. Welter
IPC分类号： G03C7/00 , G03C7/32 , G03C7/34
CPC分类号： G03C7/344 , G03C7/3212
摘要： A photographic element comprises a light sensitive silver halide emulsion layer having associated therewith a cyan dye-forming coupler dispersed in an organic solvent, the coupler having the formula: ##STR1## wherein A, B, and C are hydrogen or fluorine;X is selected from the group consisting of halogen, alkoxy and methyl groups;R is a straight chain aliphatic group which is unsubstituted or substituted with one or members selected from the group consisting of --F, --R", --OR", --SO.sub.2 R", --SO.sub.2 NHR", --CONHR", --COOR", --NHCOR", --NHSO.sub.2 R", and --OCOR" where R" is a primary or secondary alkyl group;R' is a substituent group and m is from 0 to 4;COG is hydrogen or a coupling-off group capable of being split-off by an oxidized color developer; andwherein the substituent groups X, R, and R' are selected so as to ballast the coupler and prevent it from wandering within the photographic coatings.The invention also encompasses a process for forming an image in an element as described after it has been exposed.
摘要翻译：照相元件包括光敏卤化银乳剂层，其具有分散在有机溶剂中的形成青色染料的成色剂，所述成色剂具有下式：尿素; X选自卤素，烷氧基和甲基; R是未取代的或被选自-F，-R“，-OR”，-SO 2 R“，-SO 2 NHR”，-CONHR“的一个或多个成员取代的直链脂族基团， -COOR“，-NHCOR”，-NHSO 2 R“和-OCOR”，其中R“是伯或仲烷基; R'为取代基，m为0〜4; COG是氢或能够被氧化的显色剂分离的偶合离去基团; 并且其中选择取代基X，R和R'，以便使耦合剂镇定并防止其在照相涂层内漂浮。本发明还包括用于在已经暴露之后描述的元件中形成图像的方法。

10. 发明授权

US5681690A Photographic dye-forming coupler, emulsion layer, element, and process 失效
标题翻译：摄影染料成色剂，乳剂层，元素和方法
公开(公告)号：US5681690A
公开(公告)日：1997-10-28
申请号：US622768
申请日：1996-03-27
申请人： Ping-Wah Tang , Thomas H. Jozefiak
发明人： Ping-Wah Tang , Thomas H. Jozefiak
IPC分类号： G03C7/30 , G03C7/305 , G03C7/34 , G03C1/09 , G03C7/26 , G03C7/32
CPC分类号： G03C7/346 , G03C7/30523 , G03C7/3022
摘要： The invention provides a photographic light sensitive silver halide emulsion layer having associated therewith a phenolic dye-forming coupler having the formula: ##STR1## wherein: R.sup.1 and R.sup.2 are independently selected from hydrogen and alkyl or aryl groups; R.sup.3 is a substituent group containing .beta. to the carbonyl carbon of the coupler nucleus the group --S(O).sub.n -- where n is 0 to 2; R.sup.4 is an aliphatic or aromatic group containing fluoride; R.sup.5 is hydrogen or a substituent group; and Z is hydrogen or a coupling-off group. The invention also provides a coupler compound, a photographic element containing the emulsion layer of the invention, and an imaging process.
摘要翻译：本发明提供了具有下式的酚酞染料形成成色剂的照相感光卤化银乳剂层：其中：R 1和R 2独立地选自氢和烷基或芳基; R3是与成色剂核的羰基碳的β的取代基，基团-S（O）n - ，其中n为0至2; R4是含氟的脂肪族或芳香族基团; R5是氢或取代基; Z是氢或偶合离去基团。本发明还提供了一种成色剂化合物，含有本发明的乳剂层的照相元件和成像方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式